Foresite Capital Management Iii buys $15,151,405 stake in Global Blood Therapeutics Inc (GBT)

Global Blood Therapeutics Inc (GBT) : Foresite Capital Management Iii scooped up 193,269 additional shares in Global Blood Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 690,269 shares of Global Blood Therapeutics Inc which is valued at $15,151,405.Global Blood Therapeutics Inc makes up approximately 9.68% of Foresite Capital Management Iii’s portfolio.

Other Hedge Funds, Including , Geode Capital Management boosted its stake in GBT in the latest quarter, The investment management firm added 9,282 additional shares and now holds a total of 62,715 shares of Global Blood Therapeutics Inc which is valued at $1,376,594.Fmr boosted its stake in GBT in the latest quarter, The investment management firm added 959,169 additional shares and now holds a total of 5,533,461 shares of Global Blood Therapeutics Inc which is valued at $121,459,469. Global Blood Therapeutics Inc makes up approx 0.02% of Fmr’s portfolio.Vanguard Group Inc boosted its stake in GBT in the latest quarter, The investment management firm added 443,440 additional shares and now holds a total of 1,278,464 shares of Global Blood Therapeutics Inc which is valued at $28,062,285.Diam Ltd. boosted its stake in GBT in the latest quarter, The investment management firm added 53,532 additional shares and now holds a total of 143,191 shares of Global Blood Therapeutics Inc which is valued at $2,596,053. Global Blood Therapeutics Inc makes up approx 0.04% of Diam Ltd.’s portfolio.Jennison Associates reduced its stake in GBT by selling 145 shares or 0.06% in the most recent quarter. The Hedge Fund company now holds 237,172 shares of GBT which is valued at $4,299,928.

On the company’s financial health, Global Blood Therapeutics Inc reported $-0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 10, 2016. Analyst had a consensus of $-0.63.During the same quarter in the previous year, the company posted $-4.84 EPS.

Global Blood Therapeutics Inc. is a biopharmaceutical company that engages in discovering developing and commercializing therapeutics to treat blood-based disorders. The Company is engaged in developing initial product candidate GBT440 oral prophylactic therapy for sickle cell disease (SCD). The Company offers randomized placebo-controlled double-blind single and multiple ascending dose Phase 1/2 clinical trial of GBT440 in healthy subjects and patients with SCD. It is also developing hemoglobin modifiers for pulmonary disorders such as acute respiratory distress syndrome in which increased oxygen delivery is needed. The Company through its GBT440 or analog also focuses on chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema (HAE) which is in pre-clinical trials. In addition the Company develops TBD an oral kallikrein inhibitor which are in Phase 1/2 clinical trials.

Leave a Reply

Global Blood Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Global Blood Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.